ibrutinib + rituximab + ifosfamide + carboplatin + etoposide + dexamethasone

This is a **combination chemotherapy and targeted therapy regimen** consisting of six drugs: - **Ibrutinib**: a small molecule inhibitor targeting Bruton agammaglobulinemia tyrosine kinase, which disrupts B-cell receptor signaling and inhibits survival and proliferation of malignant B cells. - **Rituximab**: a monoclonal antibody targeting CD20 on B lymphocytes, resulting in immune-mediated lysis of these cells. - **Ifosfamide**: an alkylating agent (small molecule) that crosslinks DNA strands, inhibiting DNA replication and leading to cell death. - **Carboplatin**: a platinum-based chemotherapeutic (small molecule) causing DNA crosslinking, hindering DNA synthesis and transcription. - **Etoposide**: a topoisomerase II inhibitor (small molecule), inducing DNA strand breaks and apoptosis. - **Dexamethasone**: a synthetic glucocorticoid (small molecule) with anti-inflammatory and cytotoxic effects, commonly used in oncology regimens.